<?xml version="1.0" encoding="UTF-8"?>
<search_results count="100">
  <query>disease | Closed Studies | Interventional Studies | Phase 1, 2, 3, 4, 0</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <title>Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ITF2357</intervention>
      <intervention type="Drug">Placebo capsules</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Italfarmaco</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>88 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>51</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 14, 2008</first_received>
    <start_date>October 2007</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>February 1, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the ability of ITF2357 to induce complete healing of mucosal ulcerations of ileum and/or colon, assessed by endoscopy</outcome_measure>
      <outcome_measure>to evaluate: the effect of ITF2357 on endoscopic disease activity assessed using both the CDEIS and the SESCD; the efficacy on clinical disease, assessed using the CDAI; to assess drug safety and tolerability and pharmacokinetic properties.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00792740</url>
  </study>
  <study rank="2">
    <title>Contrast-Enhanced Ultrasound in Human Crohn's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Contrast Enhanced Ultrasound</intervention>
      <intervention type="Drug">Optison</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Michigan</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>10 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>February 6, 2014</first_received>
    <start_date>February 2015</start_date>
    <completion_date>January 2018</completion_date>
    <last_updated>June 12, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluation of bowel wall inflammation and fibrosis in patients with Crohn's disease using CEUS</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02061163</url>
  </study>
  <study rank="3">
    <title>Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Polycystic Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lanreotide Autogel 90 mg and 120 mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Universitaire Ziekenhuizen Leuven</lead_sponsor>
      <collaborator>Ipsen</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 11, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>July 7, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduction of total liver volume after 6 months of treatment measured by means of CT-scan.</outcome_measure>
      <outcome_measure>Reduction of total liver volume after 12 months of treatment by means of CT-scan</outcome_measure>
      <outcome_measure>Reduction of total liver volume after 18 months of treatment by means of CT-scan</outcome_measure>
      <outcome_measure>Measurement of total liver and kidney volumes and cyst volumes at baseline.</outcome_measure>
      <outcome_measure>Measurement of total liver and kidney volumes and cyst volumes after 6 months of treatment by means of CT scan</outcome_measure>
      <outcome_measure>Measurement of total liver and kidney volume and cyst volume after 12 months of treatment by means of CT scan.</outcome_measure>
      <outcome_measure>Measurement of total liver and kidney volumes and cyst volumes after 18 months of treatment by means of CT scan</outcome_measure>
      <outcome_measure>Assessment of quality of life at baseline</outcome_measure>
      <outcome_measure>Assessment of quality of life after 6 months of treatment</outcome_measure>
      <outcome_measure>Assessment of quality of life after 12 months of treatment</outcome_measure>
      <outcome_measure>Assessment of quality of life after 18 months of treatment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01315795</url>
  </study>
  <study rank="4">
    <title>Anakinra for Behcet s Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Autoimmune/Connective Tissue Diseases</condition>
      <condition>Immune System Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anakinra</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 24, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>November 24, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Assess treatment response (number of oral ulcers/inflammatory eye disease) to anakinra over 12-16 months of observation.</outcome_measure>
      <outcome_measure>Clinical and biochemical indicators of inflammation, total number of responders, long term clinical and biochemical response, and safety.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01441076</url>
  </study>
  <study rank="5">
    <title>Phase 1 Study of Zoledronic Acid in Sickle Cell Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Zoledronic Acid</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Virginia Commonwealth University</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <first_received>March 14, 2008</first_received>
    <start_date>June 2007</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>November 10, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The long-term goal of this project is to learn if Zoledronic Acid can prevent or reduce pain in sickle cell disease.</outcome_measure>
      <outcome_measure>The specific purposes of this study are to learn if Zoledronic Acid has serious side effects for subjects with sickle cell disease and to study the effects of Zoledronic acid in subjects with sickle cell disease.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00639392</url>
  </study>
  <study rank="6">
    <title>The COPD Patient Management European Trial (COMET)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Disease Management</intervention>
      <intervention type="Other">Usual site management</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Air Liquide Santé International</lead_sponsor>
      <collaborator>ITEC Services</collaborator>
      <collaborator>Lincoln Medical and Mental Health Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>346</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <first_received>November 9, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>January 13, 2016</last_updated>
    <last_verified>January 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of unscheduled hospital days</outcome_measure>
      <outcome_measure>Number of hospital days due to severe COPD exacerbation</outcome_measure>
      <outcome_measure>Safety parameters</outcome_measure>
      <outcome_measure>Medico-economic data</outcome_measure>
      <outcome_measure>Health related quality of life</outcome_measure>
      <outcome_measure>Use of health care services</outcome_measure>
      <outcome_measure>Compliance to oxygen therapy</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01241526</url>
  </study>
  <study rank="7">
    <title>Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[18F]MK-9470</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>June 8, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>November 8, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Dynamic uptake and washout of [18F]MK-9470</outcome_measure>
      <outcome_measure>To acquire safety data</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01462708</url>
  </study>
  <study rank="8">
    <title>Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cough</condition>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Capsaicin</intervention>
      <intervention type="Other">Healthy Older Adults</intervention>
      <intervention type="Other">Parkinson's Disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 2, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>September 15, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Lung volume initiation</outcome_measure>
      <outcome_measure>Peak expiratory flow rate</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02183519</url>
  </study>
  <study rank="9">
    <title>Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
      <condition>Ophthalmologic Complications</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">graft versus host disease prophylaxis/therapy</intervention>
      <intervention type="Other">questionnaire administration</intervention>
      <intervention type="Procedure">optical coherence tomography</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fred Hutchinson Cancer Research Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <first_received>June 6, 2012</first_received>
    <start_date>June 2012</start_date>
    <last_updated>June 1, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in symptoms measured by the Lee eye subscale</outcome_measure>
      <outcome_measure>Change in patient-reported symptoms as measured by the Ocular Surface Disease Index</outcome_measure>
      <outcome_measure>Change in patient-reported symptoms as measured by the 11-point eye rating scale</outcome_measure>
      <outcome_measure>Perceived change in eye symptoms measure by the 8-level patient-perceived change</outcome_measure>
      <outcome_measure>Change in comprehensive ophthalmologic evaluations</outcome_measure>
      <outcome_measure>Change in optical coherence tomography</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01616056</url>
  </study>
  <study rank="10">
    <title>Safety and Efficacy Study of Hybrid Revascularization in Multivessel Coronary Artery Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heart Disease</condition>
      <condition>Myocardial Ischaemia</condition>
      <condition>Coronary Disease</condition>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Hybrid revascularization</intervention>
      <intervention type="Procedure">Coronary Artery Bypass Grafting</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Silesian Centre for Heart Diseases</lead_sponsor>
      <collaborator>Ministry of Science and Higher Education, Poland</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 16, 2009</first_received>
    <start_date>November 2009</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>December 1, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Possibility defined by means of (1) a % of pts with complete hybrid procedure according to study protocol, and (2) a % of conversion to standard CABG. Safety defined as a occurrence of MACE such as death, MI, stroke, TVR, or major bleeding.</outcome_measure>
      <outcome_measure>Postprocedure and follow up angiographic measurements as patency of grafts and restenosis in revascularized segments</outcome_measure>
      <outcome_measure>Assessment of quality of life of alive study participants according to SF-36 Health Survey version 2</outcome_measure>
      <outcome_measure>Cost-effectiveness defined as a cost of revascularization procedure and costs of hospitalizations in both groups.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01035567</url>
  </study>
  <study rank="11">
    <title>Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Capsule Endoscopy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Rochester</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>June 2005</start_date>
    <completion_date>June 2006</completion_date>
    <last_updated>September 16, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Compare capsule endoscopy (CE) finding with traditional findings (colonoscopy and small-bowel follow through [SBFT]) in patients with known Crohn's disease</outcome_measure>
      <outcome_measure>Evaluate the extent and severity of CE determined small-bowel involvement in patients with known Crohn's disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00178438</url>
  </study>
  <study rank="12">
    <title>Safety and Efficacy of UC-MSC in Patients With Acute Severe Graft-versus-host Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute GVH Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Human Umbilical Cord Derived MSC</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Affiliated Hospital to Academy of Military Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 11, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>April 7, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety of UC-MSC in patients with acute graft-versus-host disease</outcome_measure>
      <outcome_measure>Efficacy of UC-MSC in patients with acute graft-versus-host disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01754454</url>
  </study>
  <study rank="13">
    <title>STA-5326 in Crohn's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">STA-5326</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Synta Pharmaceuticals Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 19, 2004</first_received>
    <start_date>February 2004</start_date>
    <completion_date>November 2004</completion_date>
    <last_updated>June 23, 2005</last_updated>
    <last_verified>May 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00088062</url>
  </study>
  <study rank="14">
    <title>GM1 Ganglioside Effects on Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GM1 ganglioside</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Thomas Jefferson University</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>39 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>94</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 22, 2002</first_received>
    <start_date>November 1999</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>December 18, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>July 13, 2011</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication.</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Scores From Baseline to Week 120 Assessed Off Medication.</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Total Unified Parkinson's Disease Rating Scale (UPDRS)Score Assessed Off Medication</outcome_measure>
      <outcome_measure>Change in Total UPDRS Score From Baseline to Week 120 Assessed Off Medication</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 48 Assessed Off Medication.</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 72 Assessed Off Medication.</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 96 Assessed Off Medication.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00037830</url>
  </study>
  <study rank="15">
    <title>Home-based Disease Management Program to Improve Clinical Outcomes in Patients With Heart Failure</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heart Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Home-based disease management</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Japanese Heart Failure Outpatient Disease Management Evaluation Investigators</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>156</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>January 25, 2011</first_received>
    <start_date>January 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>May 31, 2011</last_updated>
    <last_verified>May 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Psychosocial status (depression, anxiety)</outcome_measure>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>Readmission due to heart failure</outcome_measure>
      <outcome_measure>Hospital admission</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Physical activity</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01284400</url>
  </study>
  <study rank="16">
    <title>A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CJH1 (CLR4001)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alexandra Marine and General Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 11, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>September 12, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduced signs and symptoms of Parkinson's disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01684475</url>
  </study>
  <study rank="17">
    <title>Lyme Disease Prevention Program</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lyme Disease</condition>
      <condition>Tick-Borne Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Education about disease prevention</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brigham and Women's Hospital</lead_sponsor>
      <collaborator>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</collaborator>
      <collaborator>Centers for Disease Control and Prevention</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>January 18, 2000</first_received>
    <start_date>April 1997</start_date>
    <completion_date>March 2001</completion_date>
    <last_updated>December 23, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2001</primary_completion_date>
    <outcome_measures/>
    <url>https://ClinicalTrials.gov/show/NCT00000432</url>
  </study>
  <study rank="18">
    <title>18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">18F-DTBZ</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>January 11, 2011</first_received>
    <start_date>May 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>December 25, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the sensitivity and specificity of 18F-DTBZ PET to the differential diagnosis of PD and normality for drug safety assessment</outcome_measure>
      <outcome_measure>To analyze the correlation between the regionally reduced 18F-DTBZ binding and the severity of disease of PD.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01283347</url>
  </study>
  <study rank="19">
    <title>A Trial of Wellbutrin for Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Wellbutrin (bupropion)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Altschuler, Eric, M.D.</lead_sponsor>
      <collaborator>GlaxoSmithKline</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 2, 2005</first_received>
    <start_date>May 2005</start_date>
    <completion_date>March 2006</completion_date>
    <last_updated>January 19, 2012</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients with Crohn's disease activity index (CDAI) &lt; 150 at the end of twelve weeks</outcome_measure>
      <outcome_measure>Number of patients with CDAI drop of at least 70 points at the end of twelve weeks</outcome_measure>
      <outcome_measure>Time course of CDAI</outcome_measure>
      <outcome_measure>Effect of drug and/or placebo on tumor necrosis factor-alpha (TNF) levels</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00126373</url>
  </study>
  <study rank="20">
    <title>A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Crohn's Disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ferring Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>8 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single Blind</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>September 22, 2005</first_received>
    <start_date>October 2005</start_date>
    <completion_date>February 2006</completion_date>
    <last_updated>May 18, 2011</last_updated>
    <last_verified>May 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the acceptability of Pentasa Sachets in comparison with the reference Pentasa tablets 500mg in children with Cohn's disease.</outcome_measure>
      <outcome_measure>To compare the safety of both formulations of Pentasa.</outcome_measure>
      <outcome_measure>To compare the concentration of mesalazine and N-acetylmesalazine in urine and stool during the administration of both formulations of Pentasa.</outcome_measure>
      <outcome_measure>To compare the PCD activity index at Week 4 and 8 Phase IV Study design: instead of Single Blind use Open Total enrollment: 29 patients.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00225810</url>
  </study>
  <study rank="21">
    <title>A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">[123I]β-CIT and SPECT imaging</intervention>
      <intervention type="Drug">[123I]β-CIT</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
      <collaborator>Molecular NeuroImaging</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>3000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>October 10, 2006</first_received>
    <start_date>November 2006</start_date>
    <completion_date>November 2017</completion_date>
    <last_updated>July 12, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>the mean striatal uptake of [123I]B-CIT in first-degree relatives with a loss of odor identification, compared to an established healthy control database (age 40-70; n=50)</outcome_measure>
      <outcome_measure>Estimate the frequency of olfactory loss of first-degree relatives of PD patients</outcome_measure>
      <outcome_measure>Compare striatal DAT imaging in first-degree relatives of PD patients without signs or symptoms of PD with olfactory loss to age matched healthy controls</outcome_measure>
      <outcome_measure>Determine if a reduction in DAT density using [123I]B-CIT and SPECT imaging in first-degree relatives of PD patients without signs or symptoms of PD at baseline predicts the onset of clinical PD at 2-year follow-up</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00387075</url>
  </study>
  <study rank="22">
    <title>Effect of Increlex® on Children With Crohn Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">rhIGF (Increlex)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Nationwide Children's Hospital</lead_sponsor>
      <collaborator>Tercica</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>5 Years</min_age>
    <max_age>15 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 1, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>May 14, 2015</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary outcome variable for the monitoring study (baseline, six months and disease exacerbation) will be longitudinal growth as measured by height velocity</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00764699</url>
  </study>
  <study rank="23">
    <title>Targeting Oxidative Stress in Chronic Beryllium Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Beryllium Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mesalamine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Jewish Health</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 15, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>March 19, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Beryllium lymphocyte proliferation responses (BeLPT)</outcome_measure>
      <outcome_measure>Th1 cytokines</outcome_measure>
      <outcome_measure>Steady-state GSH levels</outcome_measure>
      <outcome_measure>HDAC2 levels</outcome_measure>
      <outcome_measure>Glucocorticoid receptors</outcome_measure>
      <outcome_measure>Lung function</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01088243</url>
  </study>
  <study rank="24">
    <title>Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Adalimumab</intervention>
      <intervention type="Biological">Adalimumab</intervention>
      <intervention type="Biological">Adalimumab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>192</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 8, 2006</first_received>
    <start_date>April 2007</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>July 11, 2011</last_updated>
    <last_verified>July 2011</last_verified>
    <firstreceived_results_date>May 18, 2011</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 26</outcome_measure>
      <outcome_measure>Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 52</outcome_measure>
      <outcome_measure>Percent of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score at Week 26</outcome_measure>
      <outcome_measure>Percent of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score at Week 52</outcome_measure>
      <outcome_measure>Change From Baseline IMPACT III Scores at Week 26 (Observed Case)</outcome_measure>
      <outcome_measure>Change From Baseline IMPACT III Scores at Week 52 (Observed Case)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00409682</url>
  </study>
  <study rank="25">
    <title>Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Idiopathic Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Transdermal nicotine</intervention>
      <intervention type="Other">Usual drug treatment of Parkinson's disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>35 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 31, 2009</first_received>
    <start_date>February 2009</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>December 29, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Comparison of motor scores in defined off condition : UPDRS III motor score assessed in &quot;defined OFF&quot; condition in comparison with control group.</outcome_measure>
      <outcome_measure>Evaluation of UPDRS III motor score assessed in &quot;defined OFF&quot; condition</outcome_measure>
      <outcome_measure>Improvement of UPDRS III motor score assessed in &quot;defined ON&quot; condition</outcome_measure>
      <outcome_measure>Evaluation of motor benefit (UPDRS &quot;OFF&quot; and &quot;ON&quot;)</outcome_measure>
      <outcome_measure>Evaluation of neuroprotection, (SPECT DaTSCAN and UPDRS &quot;OFF&quot;)</outcome_measure>
      <outcome_measure>Persistence of motor benefit (UPDRS &quot;OFF&quot; and &quot;ON&quot;)</outcome_measure>
      <outcome_measure>Decrease of total daily L-Dopa dose (or calculated equivalent in case of polytherapy)</outcome_measure>
      <outcome_measure>Improvement of quality of life (ADL and PDQ 39 scales)</outcome_measure>
      <outcome_measure>Decrease of daily percentage of &quot;OFF&quot; phase</outcome_measure>
      <outcome_measure>Improvement of dyskinesia score, (UPDRS IV)</outcome_measure>
      <outcome_measure>Relation dose / effect of nicotine</outcome_measure>
      <outcome_measure>Estimation of the most effective and tolerated dose of nicotine per kg</outcome_measure>
      <outcome_measure>Improvement of cognitive functions assessed by Mattis scale</outcome_measure>
      <outcome_measure>Comparison of all parameters between the 2 groups of patients</outcome_measure>
      <outcome_measure>Compliance to nicotine treatment</outcome_measure>
      <outcome_measure>Tolerance of transdermal nicotine</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00873392</url>
  </study>
  <study rank="26">
    <title>Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CEP-1347 10mg</intervention>
      <intervention type="Drug">CEP1347 25mg</intervention>
      <intervention type="Drug">CEP-1347 50mg</intervention>
      <intervention type="Other">Placebo Comparator</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cephalon</lead_sponsor>
      <collaborator>H. Lundbeck A/S</collaborator>
      <collaborator>The Parkinson Study Group</collaborator>
      <collaborator>Teva Pharmaceutical Industries</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>806</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 26, 2002</first_received>
    <start_date>March 2002</start_date>
    <completion_date>August 2005</completion_date>
    <last_updated>May 8, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with disability using United Parkinson's Disease Rating Scale (UPDRS)</outcome_measure>
      <outcome_measure>Change from Baseline to 22 months in ([123I]β-CIT) Uptake Participants</outcome_measure>
      <outcome_measure>Safety and Tolerability as assessed by the number of participants experiencing adverse events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00040404</url>
  </study>
  <study rank="27">
    <title>A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Sensorineural Hearing Loss</condition>
      <condition>Autoimmune Inner Ear Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anakinra</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Andrea Vambutas</lead_sponsor>
      <collaborator>National Institute on Deafness and Other Communication Disorders (NIDCD)</collaborator>
      <collaborator>Northwell Health</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>13 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 28, 2010</first_received>
    <start_date>June 2011</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>March 23, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>September 16, 2014</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To Assess the Potential Efficacy of Anakinra in Improving Hearing Thresholds in Corticosteroid-resistant Patients With Autoimmune Inner Ear Disease</outcome_measure>
      <outcome_measure>To Assess the Safety and Tolerability of a Three Month (84 Day) Course of Anakinra in Corticosteroid Resistant Patients With Autoimmune Inner Ear Disease.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01267994</url>
  </study>
  <study rank="28">
    <title>Subthalamic Deep Brain Stimulation (DBS) in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Transcranial Magnetic Stimulation (TMS)</intervention>
      <intervention type="Procedure">Motor Physiology Testing</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>November 1, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>June 9, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Motor Cortex Excitability</outcome_measure>
      <outcome_measure>Relation between Unified Parkinson's Disease Rating Scale outcomes and physiological measures</outcome_measure>
      <outcome_measure>Transcallosal Pathway Excitability</outcome_measure>
      <outcome_measure>Physiological Measures</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02012647</url>
  </study>
  <study rank="29">
    <title>Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Infliximab with azathioprine (IIFX + AZA)</intervention>
      <intervention type="Drug">Infliximab (IFX alone)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Children's Memorial Health Institute, Poland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>7 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 19, 2012</first_received>
    <start_date>November 2008</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>April 2, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical disease activity</outcome_measure>
      <outcome_measure>endoscopic disease activity</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01559142</url>
  </study>
  <study rank="30">
    <title>An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Infliximab 5 mg/kg</intervention>
      <intervention type="Drug">Infliximab 10 mg/kg</intervention>
      <intervention type="Drug">Infliximab 20 mg/kg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Centocor, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>108</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 22, 2005</first_received>
    <start_date>June 1995</start_date>
    <completion_date>October 1996</completion_date>
    <last_updated>November 3, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 1996</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Comparison of the proportion of patients achieving a clinical response at Week 4</outcome_measure>
      <outcome_measure>Clinical response over time; Time to loss of response; Clinical remission over time; Changes in CDAI, Inflammatory Bowel Disease Questionnaire (IBDQ) and Crohn's Disease Endoscopic Index of Severity (CDEIS) scores and C-reactive protein values</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00269854</url>
  </study>
  <study rank="31">
    <title>Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[18F] PBR111</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>September 20, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>November 8, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the cerebral distribution of [18F]PBR-111 positron emission tomography (PET) for detection/exclusion of microglial activation in patients with Alzheimer Disease compared to healthy volunteers.</outcome_measure>
      <outcome_measure>To assess the dynamic uptake and washout of [18F]PBR-111, a potential imaging biomarker for inflammatory changes in brain, using positron emission tomography (PET) in Alzheimer disease subjects compared to healthy volunteers.</outcome_measure>
      <outcome_measure>To perform blood metabolite characterization of [18F]PBR-111 in AD subjects compared to Healthy volunteers to determine the nature of metabolites in assessment of [18F]PBR-111 as a single positron computed tomography (PET) brain imaging agent.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01209156</url>
  </study>
  <study rank="32">
    <title>Rapamycin for Prevention of Chronic Graft-Versus-Host Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft Versus Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rapamycin</intervention>
      <intervention type="Drug">Tacrolimus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 13, 2008</first_received>
    <start_date>February 2008</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>July 15, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement of the rate of graft versus host disease (GVHD) from the accepted rate of 74%.</outcome_measure>
      <outcome_measure>Overall survival and disease free survival</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00623012</url>
  </study>
  <study rank="33">
    <title>Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">bowel prep regimen first boost 6 oz. and second boost 3 oz.</intervention>
      <intervention type="Other">bowel prep regimen first boost 3 oz. and second boost 6 oz.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Given Imaging Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>April 5, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>October 5, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>October 5, 2014</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>• Evaluate the Effectiveness of the PillCam COLON 2 Bowel Prep Regimen in Crohn's Disease Patients</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01576120</url>
  </study>
  <study rank="34">
    <title>Self-Management Addressing Heart Disease Risk Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Bipolar Disorder</condition>
      <condition>Cardiovascular Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Chronic care model for Bipolar Disorder</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>118</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <first_received>July 9, 2007</first_received>
    <start_date>May 2008</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>November 12, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>October 17, 2014</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Systolic and Diastolic Blood Pressure (SBP, DBP)</outcome_measure>
      <outcome_measure>Total Cholesterol</outcome_measure>
      <outcome_measure>Physical Health-related Quality of Life Score</outcome_measure>
      <outcome_measure>Manic Symptoms</outcome_measure>
      <outcome_measure>Depressive Symptom Score</outcome_measure>
      <outcome_measure>Disability Based on WHO-DAS Score</outcome_measure>
      <outcome_measure>Body Mass Index (BMI)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00499096</url>
  </study>
  <study rank="35">
    <title>Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">I-123-MNI-168</intervention>
      <intervention type="Drug">123-I MNI-168</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>March 26, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>February 24, 2011</last_updated>
    <last_verified>February 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the uptake and washout of {I123}MNI-168, a potential imaging biomarker for β-amyloid burden in brain,</outcome_measure>
      <outcome_measure>To acquire initial safety data following injection of (123I) MNI-168.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00870519</url>
  </study>
  <study rank="36">
    <title>Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sargramostim (Leukine)</intervention>
      <intervention type="Drug">Sargramostim (Leukine)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Genzyme, a Sanofi Company</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>16 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 12, 2005</first_received>
    <start_date>December 2004</start_date>
    <completion_date>December 2006</completion_date>
    <last_updated>December 2, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Characterize the safety profile of sargramostim treatment with concomitant corticosteroid induction therapy</outcome_measure>
      <outcome_measure>Characterize the pharmacokinetic, pharmacodynamics properties of sargramostim treatment with concomitant corticosteroid induction therapy</outcome_measure>
      <outcome_measure>Evaluate the efficacy of sargramostim treatment with concomitant corticosteroids as measured by the Pediatric Crohn's Disease Activity Index (PCDAI), Physician's Global Assessment (PGA), and IMPACT-III Questionnaire</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00206661</url>
  </study>
  <study rank="37">
    <title>Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">lipoic acid and fish oil concentrate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Oregon Health and Science University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>January 27, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>May 7, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Activities of Daily Living and Alzheimer's Disease Assessment Scale - cognitive subscale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01058941</url>
  </study>
  <study rank="38">
    <title>Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes Mellitus, With Complications</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Intravenous Insulin on cardiac disease in diabetic pts</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Florida Atlantic University</lead_sponsor>
      <collaborator>Advanced Diabetes Treatment Centers</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 3, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>August 8, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Monitor and assess whether Pulsatile Intravenous Insulin Therapy can effect progression of cardiac disease in diabetic patients. Monitor results of Cardiac tests,carotid ultrasounds and echocardiograms,cardiac QOL, labs, meds to analyze progress.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00539435</url>
  </study>
  <study rank="39">
    <title>Topical Imiquimod for Bowen's Disease of the Head and Neck</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Bowens Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Imiquimod</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brooke Army Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 4, 2006</first_received>
    <start_date>November 2006</start_date>
    <last_updated>March 25, 2008</last_updated>
    <last_verified>March 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>histologic clearance of Bowens disease in treated versus placebo group</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00384124</url>
  </study>
  <study rank="40">
    <title>Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>98</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 12, 2005</first_received>
    <start_date>August 2005</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>May 30, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Crohn's Disease Activity Index (CDAI)</outcome_measure>
      <outcome_measure>Clinical response; remission; change in C-reactive protein; reduction in steroid use; fistula response; change in Perianal Disease Activity Index (PDAI); change in plasma cytokine levels</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00130390</url>
  </study>
  <study rank="41">
    <title>ESCAP: Supervised Exercise for Patients With Coronary Heart Disease in the Primary Care Setting</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Heart Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Supervised exercise on a stationary bicycle, 3-5 days a week</intervention>
      <intervention type="Behavioral">Secondary prevention program for coronary heart disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Basque Health Service</lead_sponsor>
      <collaborator>Preventive Services and Health Promotion Research Network</collaborator>
      <collaborator>Santa Bárbara and Cuenca primary care centers(Castilla La Mancha Health Service)</collaborator>
      <collaborator>Castilla-León Health Service</collaborator>
      <collaborator>Dalt Sant Joan primary care center (Balears Islans Health Service)</collaborator>
      <collaborator>Public Health Service of Cataluña</collaborator>
      <collaborator>Public Health Service of Madrid</collaborator>
      <collaborator>Public Health Service of Galicia</collaborator>
      <collaborator>Cantabria Health Service</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>97</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 6, 2005</first_received>
    <start_date>January 2005</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>May 31, 2011</last_updated>
    <last_verified>May 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Functional capacity (exercise treadmill test)</outcome_measure>
      <outcome_measure>Health Related Quality of life (SF-36)</outcome_measure>
      <outcome_measure>Cardiovascular risk factor control</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00146315</url>
  </study>
  <study rank="42">
    <title>Umbilical Cord Mesenchymal Stem Cells Injection for Diabetes Secondary Peripheral Arterial Disease</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes</condition>
      <condition>Peripheral Arterial Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">umbilical cord mesenchymal stem cells</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute of Hematology &amp; Blood Diseases Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 2, 2014</first_received>
    <start_date>February 2014</start_date>
    <last_updated>February 24, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Angiographic evaluation of angiogenesis at ischemic limb</outcome_measure>
      <outcome_measure>Ankle-Brachial pressure index</outcome_measure>
      <outcome_measure>Walking distance</outcome_measure>
      <outcome_measure>Pain</outcome_measure>
      <outcome_measure>Laser Doppler evaluation of blood perfusion at ischemic limb</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02287831</url>
  </study>
  <study rank="43">
    <title>Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Graft-Versus-Host Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cyclosporine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Universitario Dr. Jose E. Gonzalez</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>May 13, 2014</first_received>
    <start_date>May 2014</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>February 25, 2016</last_updated>
    <last_verified>February 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Ocular graft versus host disease is manifested by dry eye syndrome and disruptions in corneal integrity. The study will asses the efficacy of topical cyclosporine for preventing OGVHD manifestations</outcome_measure>
      <outcome_measure>Characteristics and clinical presentation of ocular graft versus host disease in patients receiving allogeneic bone marrow transplantation using a reduced intensity conditioning regimen</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02144025</url>
  </study>
  <study rank="44">
    <title>New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Glioblastoma</condition>
      <condition>Sarcoma</condition>
      <condition>Neuroblastoma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">New Castle Disease Virus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hadassah Medical Organization</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>3 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 2, 2010</first_received>
    <start_date>July 2011</start_date>
    <completion_date>July 2011</completion_date>
    <last_updated>June 10, 2015</last_updated>
    <last_verified>August 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Progression-free survival</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01174537</url>
  </study>
  <study rank="45">
    <title>Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ONO-2506PO</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ono Pharmaceutical Co. Ltd</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 13, 2005</first_received>
    <start_date>January 2004</start_date>
    <last_updated>October 10, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Unified Parkinson's disease rating scale (Part III)</outcome_measure>
      <outcome_measure>Unified Parkinson's disease rating scale (Part I, II, IV and total), revised Hoehn &amp; Yahr severity score and off time</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00212693</url>
  </study>
  <study rank="46">
    <title>Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Autologous mesenchymal stem cells</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Clinica Universidad de Navarra, Universidad de Navarra</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 5, 2010</first_received>
    <start_date>June 2010</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>November 7, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Security and tolerance</outcome_measure>
      <outcome_measure>therapeutic effect</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01157650</url>
  </study>
  <study rank="47">
    <title>A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SEN0014196</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Siena Biotech S.p.A.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>25 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 29, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>March 19, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the effect of food on the repeated dose pharmacokinetics of SEN0014196 at 100 mg once daily in subjects with Huntington's disease</outcome_measure>
      <outcome_measure>Pharmacodynamics</outcome_measure>
      <outcome_measure>To determine the safety and tolerability of repeated doses of SEN0014196 at 100 mg once daily in subjects with Huntington's disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01485965</url>
  </study>
  <study rank="48">
    <title>Alzheimer's Disease: Therapeutic Potential of Estrogen</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Transdermal estradiol</intervention>
      <intervention type="Drug">Medroxyprogesterone</intervention>
      <intervention type="Drug">Placebo Patch</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Wisconsin, Madison</lead_sponsor>
      <collaborator>National Institute on Aging (NIA)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 4, 2003</first_received>
    <start_date>September 2001</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>September 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cognition: delayed recall on Buschke Selective Reminding Test; Stroop Interference condition--completion time and errors; Clinician-rated Interview Based Impression of Change</outcome_measure>
      <outcome_measure>Skills of Independent Living: Physical functioning Performance (PFP)</outcome_measure>
      <outcome_measure>Bioassays (Estradiol, estrone, medroxyprogesterone, FSH, influence of ApoE genotype in responsivity to estrogen)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00066157</url>
  </study>
  <study rank="49">
    <title>Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[18F] CFPyPB</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <first_received>September 27, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>June 2, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the dynamic uptake and washout of [18F] CFPyPB</outcome_measure>
      <outcome_measure>Perform blood metabolite characterization of [18F] CFPyPB</outcome_measure>
      <outcome_measure>To obtain safety data</outcome_measure>
      <outcome_measure>Obtain test/retest reproductibility</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01461109</url>
  </study>
  <study rank="50">
    <title>Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Isotretinoin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospitals Cleveland Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 15, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>August 27, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from Baseline to Six month timepoint in the score on the Alzheimer's disease Assessment Scale- Cognitive subscale</outcome_measure>
      <outcome_measure>Number and types of adverse effects</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01560585</url>
  </study>
  <study rank="51">
    <title>A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Human Placenta-Derived Cells PDA001 Intravenous Infusion</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Celgene Corporation</lead_sponsor>
      <collaborator>Celgene</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 26, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>July 14, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>A reduction from baseline by 25% and/or &gt; 100 points in the Crohn's Disease Activity Index (CDAI) scores at both Week 4 (Day 29) and at Week 6 (Day 43).</outcome_measure>
      <outcome_measure>The induction of a clinical remission defined as a Crohn's Disease Activity Index score of &lt; 150 points at both Week 4 (Day 29) and Week 6 (Day 43)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01155362</url>
  </study>
  <study rank="52">
    <title>Development of Cognitive Assessment Tools in Parkinson Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[123I] IBVM and SPECT imaging</intervention>
      <intervention type="Drug">Subjects will undergo the 123-I IBVM imaging visit</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
      <collaborator>University of Oklahoma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <first_received>November 8, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>March 2011</completion_date>
    <last_updated>February 8, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The overall goal of this proposal is to validate ANAM-PD as an assessment tool for cognitive status in PD</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00556764</url>
  </study>
  <study rank="53">
    <title>Efficiency of Radiofrequency Ablation for Surgical Treatment of Chronic Atrial Fibrillation With Rheumatic Valve Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Rheumatic Valve Disease</condition>
      <condition>Atrial Fibrillation</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Cardioblate® Surgical Ablation System</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>China National Center for Cardiovascular Diseases</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 11, 2009</first_received>
    <start_date>March 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>November 16, 2009</last_updated>
    <last_verified>November 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>At 3rd, 6th and 12th month's follow-up, to evaluate the rhythm status by ECG and 24-hour Holter and cardiac hemodynamic status by transthoracic echocardiography</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01013688</url>
  </study>
  <study rank="54">
    <title>Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Certolizumab pegol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>106</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 25, 2006</first_received>
    <start_date>January 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>August 26, 2014</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>February 23, 2011</firstreceived_results_date>
    <primary_completion_date>February 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Occurrence of at Least One Treatment-emergent Adverse Event During This Study (Maximum 122 Weeks)</outcome_measure>
      <outcome_measure>Disease Remission (Crohn's Disease Activity Index, CDAI≤150) at Week 34 in Patients Who Completed/Did Not Complete C87059 (COSPAR I, NCT00349752) and Remained Off Corticosteroids.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00356408</url>
  </study>
  <study rank="55">
    <title>Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Hematopoietic stem cell transplantation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>7 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 28, 2013</first_received>
    <start_date>February 2014</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>April 13, 2016</last_updated>
    <last_verified>April 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary outcome to be measured is safety and clinical benefit of lymphoablation followed by autologous HSCT rescue in therapy refractory Crohn's disease.</outcome_measure>
      <outcome_measure>Disease remission</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01932658</url>
  </study>
  <study rank="56">
    <title>Vaccination Against Influenza in Autoimmune Diseases</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Autoimmune Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Evaluation of vaccines against flu</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>234</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 21, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>January 5, 2016</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Protection against H1N1 influenza, defined by antibody level of 1/40, measured by hemagglutination, 3 weeks after the first injection and after the second injection</outcome_measure>
      <outcome_measure>Antibody levels against H1N1 in the different groups of patients, defined according diseases and their treatment (comparison of patients treated by immunosuppressants or not treated)</outcome_measure>
      <outcome_measure>Number of side effects related to vaccination</outcome_measure>
      <outcome_measure>Number of local side effects related to vaccination (erythema and/or pain at injection site)</outcome_measure>
      <outcome_measure>Number of patients who will develop influenza despite vaccination</outcome_measure>
      <outcome_measure>Number of patients who had antibodies against H1N1 before vaccination</outcome_measure>
      <outcome_measure>Number of hospitalisations and deaths related to influenza</outcome_measure>
      <outcome_measure>Number of flares of the autoimmune diseases that could be related to vaccination</outcome_measure>
      <outcome_measure>Determine if the induction of LT-CD4 to J21-28 anti-jams is correlated to the concentrations of antibody anti-vaccines measured in 6 months</outcome_measure>
      <outcome_measure>Determine if the basal concentrations of LT-CD4 anti-jam to J21-J28 are correlated to the concentrations of antibody anti-vaccines measured in 6 months</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01065285</url>
  </study>
  <study rank="57">
    <title>Trial of a Treatment Algorithm for the Management of Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Treatment Algorithm for Crohn's Disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Western Ontario, Canada</lead_sponsor>
      <collaborator>Abbott</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1999</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 9, 2009</first_received>
    <start_date>January 2010</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>March 19, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients in remission at the end of the 24 month followup period. Remission is defined as a HBS&lt; or = 4 without use of steroids for the treatment of CD. the primary analysis will be performed at the level of the practice.</outcome_measure>
      <outcome_measure>Proportion of patients in remission over study, change in mean HBS; use of CD meds, occurrence of surgery/hospitalization for CD and complications, patients' health related QOL measured by SF-36 &amp; EQ-5D; physician/patient satisfaction with therapy.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01030809</url>
  </study>
  <study rank="58">
    <title>Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">CERE-110: Adeno-Associated Virus Delivery of NGF</intervention>
      <intervention type="Procedure">Placebo Surgery</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ceregene</lead_sponsor>
      <collaborator>Alzheimer's Disease Cooperative Study (ADCS)</collaborator>
      <collaborator>Sangamo Biosciences</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 3, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>March 2020</completion_date>
    <last_updated>October 27, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)</outcome_measure>
      <outcome_measure>Neuropsychological Test Battery</outcome_measure>
      <outcome_measure>Mini-Mental State Examination (MMSE)</outcome_measure>
      <outcome_measure>Neuropsychiatric Inventory (NPI)</outcome_measure>
      <outcome_measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00876863</url>
  </study>
  <study rank="59">
    <title>A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">QAX576</intervention>
      <intervention type="Drug">Infliximab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 16, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Assessment of efficacy of QAX576 to induce complete closure for at least 4 weeks of all perianal fistulas in patients suffering from Crohn's disease by: clinical observation and cutaneous photodocumentation</outcome_measure>
      <outcome_measure>Assessment of safety and tolerability of QAX576 in patients suffering from Crohn's disease as measured by lab assessments, ECG, physical exam etc</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01355614</url>
  </study>
  <study rank="60">
    <title>Influenza Vaccination in Prevention From Acute Coronary Events in Coronary Artery Disease - FLUCAD Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Influenza vaccination: Influvac (SolvayPharma)</intervention>
      <intervention type="Biological">placebo influenza vaccine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute of Cardiology, Warsaw, Poland</lead_sponsor>
      <collaborator>Solvay Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>658</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>August 31, 2006</first_received>
    <start_date>October 2004</start_date>
    <completion_date>December 2005</completion_date>
    <last_updated>October 21, 2007</last_updated>
    <last_verified>October 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>cardiovascular death</outcome_measure>
      <outcome_measure>First composite study end point was Major Adverse Cardiac Event (MACE). MACE was combined of: cardiovascular death, acute myocardial infarction (MI), coronary revascularization (PCI or coronary bypass).</outcome_measure>
      <outcome_measure>Second composite study end point was Ischemic Event (MACE or hospitalization for ischemia).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00371098</url>
  </study>
  <study rank="61">
    <title>Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">adalimumab</intervention>
      <intervention type="Drug">prednisone</intervention>
      <intervention type="Drug">azathioprine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>255</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 4, 2010</first_received>
    <start_date>February 2011</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>November 16, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of mucosal healing as defined by the Crohn's Disease Endoscopic Index of Severity (CDEIS) score at 48 weeks after Randomization</outcome_measure>
      <outcome_measure>Assess Pharmacokinetics (PK) of adalimumab following subcutaneous injection; a PK blood draw at protocol defined time points. Serum concentrations of adalimumab will be determined using a validated Ligand binding assay (LBA) method.</outcome_measure>
      <outcome_measure>Safety will be assessed through clinical laboratory tests, vital signs, physical exams and adverse event assessments.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01235689</url>
  </study>
  <study rank="62">
    <title>A Trial of Multi-convergent Therapy for Functional Symptoms and Stress in Patients With Inflammatory Bowel Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Multi-Convergent Therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cardiff and Vale University Health Board</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 26, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>August 27, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Quality of Life in Inflammatory Bowel Disease Questionnaire</outcome_measure>
      <outcome_measure>Change in Irritable Bowel Syndrome Symptom Severity Score</outcome_measure>
      <outcome_measure>Change in Levenstein Perceived Stress Score</outcome_measure>
      <outcome_measure>Change in Hospital Anxiety and Depression Score</outcome_measure>
      <outcome_measure>Abdominal Symptoms Global Improvement Score</outcome_measure>
      <outcome_measure>Relapse rate in inflammatory bowel disease</outcome_measure>
      <outcome_measure>Feasibility of Treatment</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01426568</url>
  </study>
  <study rank="63">
    <title>A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VSL#3</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Federico II University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>5 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 25, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>August 10, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>to evaluate the effect of a probiotic formulation, VSL#3, versus placebo, on metabolic profile, intestinal permeability, microbiota, cytokines and chemokines expression and other inflammatory markers in pediatric patients with Crohn's Disease</outcome_measure>
      <outcome_measure>To determine the effect on Pediatric Crohn Disease Activity Index (PCDAI);</outcome_measure>
      <outcome_measure>to determine the time till flare of CD pediatric patients on VSL#3 compared to placebo.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01632462</url>
  </study>
  <study rank="64">
    <title>Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Meniere's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Betahistine 24 mg bid (Betaserc)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Solvay Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 9, 2005</first_received>
    <start_date>January 2003</start_date>
    <last_updated>December 21, 2006</last_updated>
    <last_verified>December 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Patients who have undergone vestibular neurotomy for the treatment of disabling Menière’s disease and who have confirmed vestibular areflexia</outcome_measure>
      <outcome_measure>Other peripheral vestibular disease than Menière’s disease;Central vestibular disease; Neurological disease; Contraindication to betahistine; Pregnant or lactating women</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00160238</url>
  </study>
  <study rank="65">
    <title>Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Measurement of serum infliximab and anti-infliximab antibodies</intervention>
      <intervention type="Procedure">Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Copenhagen University Hospital at Herlev</lead_sponsor>
      <collaborator>Aase and Ejnar Danielsens Foundation</collaborator>
      <collaborator>Beckett Foundation</collaborator>
      <collaborator>the Danish Biotechnology Program</collaborator>
      <collaborator>Colitis-Crohn Foreningen</collaborator>
      <collaborator>Danish Medical Association</collaborator>
      <collaborator>Frode V. Nyegaard and wife’s Foundation</collaborator>
      <collaborator>Health Science Research Foundation of Region of Copenhagen</collaborator>
      <collaborator>Herlev Hospital Research Council</collaborator>
      <collaborator>Lundbeck Foundation</collaborator>
      <collaborator>P. Carl Petersens Fund</collaborator>
      <collaborator>Biomonitor A/S</collaborator>
      <collaborator>Prometheus Inc.</collaborator>
      <collaborator>The Danish Institute for Health Services Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 24, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>November 24, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients with response at week 12, i.e. CDAI decrease of 70 or more for patients with luminal disease, or reduction of 50 percent or more from base line in the number of draining fistulas for patients with fistulising disease.</outcome_measure>
      <outcome_measure>Total expenses related to Crohn's disease during the study (inclusion to week 12).</outcome_measure>
      <outcome_measure>Mean change compared to baseline in WPAI score at week 12.</outcome_measure>
      <outcome_measure>Mean change compared to baseline in IBDQ score at week 12.</outcome_measure>
      <outcome_measure>Mean change compared to baseline in CDAI score at week 4,8, 12,20.</outcome_measure>
      <outcome_measure>Mean change compared to baseline in PDAI score at week 4, 8, 12, and 20.</outcome_measure>
      <outcome_measure>Clinical response at week 4, 8, 20</outcome_measure>
      <outcome_measure>Laboratory parameters</outcome_measure>
      <outcome_measure>Days with subjective feeling of disability due to Crohn's disease</outcome_measure>
      <outcome_measure>Serious adverse drug reactions</outcome_measure>
      <outcome_measure>Expenses related to Crohn's diseae at week 20</outcome_measure>
      <outcome_measure>Expenses related to Crohn's disease compared to change in CDAI-score (luminal disease) or PDAI-score (fistulizing disease), and IBD-score at week 12 and 20</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00851565</url>
  </study>
  <study rank="66">
    <title>African American Community Health Project on Cardiovascular Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Diseases</condition>
      <condition>Cardiovascular Risk Factor</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">lecture</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Northwestern University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>April 4, 2011</first_received>
    <start_date>October 2010</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>April 12, 2011</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Blood pressure</outcome_measure>
      <outcome_measure>Weight</outcome_measure>
      <outcome_measure>Body mass index</outcome_measure>
      <outcome_measure>Waist Circumference</outcome_measure>
      <outcome_measure>Multiple choice test on cardiovascular disease</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01335022</url>
  </study>
  <study rank="67">
    <title>An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">galantamine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>398</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>March 10, 2006</first_received>
    <start_date>April 2001</start_date>
    <completion_date>February 2004</completion_date>
    <last_updated>May 16, 2011</last_updated>
    <last_verified>January 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change from baseline to the end of the study in the Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) and the Clinician's Interview-Based Impression of Change plus - Japan (CIBIC plus-J)</outcome_measure>
      <outcome_measure>Change from baseline to the end of the study in CIBIC plus-J subscales (Disability Assessment for Dementia [DAD], Behavioral Pathology in Alzheimer's Disease Rating Scale [Behave-AD], the Mental Function Impairment Scale [MENFIS ]).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00301574</url>
  </study>
  <study rank="68">
    <title>A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
      <condition>Dementia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Drug: NIC5-15</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanetics Corporation</lead_sponsor>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
      <collaborator>James J. Peters Veterans Affairs Medical Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>95 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 17, 2012</first_received>
    <start_date>April 2007</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>October 14, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score</outcome_measure>
      <outcome_measure>Change in Alzheimer's Disease Cooperative Study Clinician's Global Impression of Change (ADCS-CCGIC) Score</outcome_measure>
      <outcome_measure>Change in Mini-Mental State Examination (MMSE) Score</outcome_measure>
      <outcome_measure>Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Score</outcome_measure>
      <outcome_measure>Change in Neuropsychiatric Inventory (NPI) Score</outcome_measure>
      <outcome_measure>Changes in AD Biomarkers</outcome_measure>
      <outcome_measure>APO-E genotyping</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01928420</url>
  </study>
  <study rank="69">
    <title>Capsule Endoscopy Crohn's Disease Activity Index - Validation Multi Center Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Given® Diagnostic System including PillCamTM SB Capsules</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Rabin Medical Center</lead_sponsor>
      <collaborator>VA Office of Research and Development</collaborator>
      <collaborator>Rambam Health Care Campus</collaborator>
      <collaborator>Assaf-Harofeh Medical Center</collaborator>
      <collaborator>Hillel Yaffe Medical Center</collaborator>
      <collaborator>University of Athens</collaborator>
      <collaborator>University of Magdeburg</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>January 8, 2008</first_received>
    <start_date>January 2007</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>April 28, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>This prospective study is aimed to evaluate the correlation of capsule endoscopy CECDAI with the CDAI (accepted clinical index) and IBDQ (quality of life questionnaire) in patients suffering from small-bowel Crohn's disease</outcome_measure>
      <outcome_measure>Capsule endoscopy investigation and crohn's disease outcome</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00596700</url>
  </study>
  <study rank="70">
    <title>A Study of the Novel Drug Dimebon in Patients With Huntington's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Huntington's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Placebo</intervention>
      <intervention type="Drug">Dimebon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medivation, Inc.</lead_sponsor>
      <collaborator>Huntington Study Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>29 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>91</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 3, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>May 16, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the safety and tolerability of Dimebon during 3 months of treatment in subjects with Huntington's Disease.</outcome_measure>
      <outcome_measure>To assess the impact of Dimebon during 3 months of treatment on cognitive, motor, and overall function in subjects with Huntington's Disease.</outcome_measure>
      <outcome_measure>To assess the pharmacokinetics of Dimebon.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00497159</url>
  </study>
  <study rank="71">
    <title>The Effects of Naltrexone on Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Inflammation</condition>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Naltrexone-HCl</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Penn State University</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
      <collaborator>The Broad Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>April 18, 2008</first_received>
    <start_date>September 2006</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>May 16, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>November 30, 2012</firstreceived_results_date>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects Achieving a 70-point Decline in CDAI Scores (Crohn's Disease Activity Index) Scores;</outcome_measure>
      <outcome_measure>Percentage Change From Baseline of Quality of Life IBDQ (Inflammatory Bowel Disease Quality of Life Survey)</outcome_measure>
      <outcome_measure>Percentage of Patients With a 5 Point Drop in CDEIS Score by Endoscopy</outcome_measure>
      <outcome_measure>Histology Inflammatory Score by Colon Biopsies</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00663117</url>
  </study>
  <study rank="72">
    <title>Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">adult human mesenchymal stem cells</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mesoblast International Sàrl</lead_sponsor>
      <collaborator>Mesoblast, Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>330</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 30, 2007</first_received>
    <start_date>May 2007</start_date>
    <completion_date>December 2018</completion_date>
    <last_updated>October 27, 2016</last_updated>
    <last_verified>October 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Disease remission (CDAI at or below 150)</outcome_measure>
      <outcome_measure>Disease improvement (Reduction by at least 100 points in CDAI)</outcome_measure>
      <outcome_measure>Improvement in quality of life (IBDQ)</outcome_measure>
      <outcome_measure>Reduction in number of draining fistulas</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00482092</url>
  </study>
  <study rank="73">
    <title>Comprehensive Evaluation of Ischemic Heart Disease Using MRI</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Heart Disease, Ischemic</condition>
      <condition>Atherosclerosis, Coronary</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Gadolinium</intervention>
      <intervention type="Drug">Adenosine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Northwestern University</lead_sponsor>
      <collaborator>Astellas Pharma US, Inc.</collaborator>
      <collaborator>Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>October 5, 2010</first_received>
    <start_date>June 2010</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>September 25, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>September 2, 2014</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Magnetic Resonance Image Quality Rating</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events to Demonstrate Feasibility of a Comprehensive Cardiac Magnetic Resonance Imaging Protocol</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01234870</url>
  </study>
  <study rank="74">
    <title>Evaluation of the Effect of Repetitive Transcranial Magnetic Stimulation in Pain Perception in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Repetitive Transcranial Magnetic Stimulation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Toulouse</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <first_received>December 10, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>June 18, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change of subjective pain threshold determined using thermal stimulation (Thermotest) with the method of levels after rTMS session</outcome_measure>
      <outcome_measure>Analgesic effect of Repetitive Transcranial Magnetic Stimulation using Visual Analogue Scale</outcome_measure>
      <outcome_measure>- Clinical evaluation of the severity of the motor handicap of patients using Unified's Parkinson's Disease Rating Scale (UPDRSIII)</outcome_measure>
      <outcome_measure>Mood assessment using Visual Analogue Scale</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01275573</url>
  </study>
  <study rank="75">
    <title>Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>IDIOPATHIC PARKINSON'S DISEASE</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rotigotine</intervention>
      <intervention type="Drug">Placebo Patch</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>249</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 18, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>July 14, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>May 20, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in the Sum of the Score From the Activities of Daily Living (ADL) Scale and Motor Examination in the Unified Parkinson's Disease Rating Scale (UPDRS) (Parts II+III, a UPDRS Subtotal) From Baseline to the End of Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Response to Therapy, Defined as ≥20 % Decrease in the Sum of Scores From Activities of Daily Living (ADL) &amp; Motor Examination in Unified Parkinson's Disease Rating Scale (UPDRS Parts II+III, a UPDRS Subtotal) From Baseline to End of Maintenance Period</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale [UPDRS Part II (ADL)] From Baseline to the End of the Double-blind Maintenance Period</outcome_measure>
      <outcome_measure>Change in Unified Parkinson's Disease Rating Scale [UPDRS Part III (Motor Examination)] From Baseline to the End of the Double-blind Maintenance Period</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01646268</url>
  </study>
  <study rank="76">
    <title>Pioglitazone in Early Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pioglitazone</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Rochester</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
      <collaborator>Michael J. Fox Foundation for Parkinson's Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 3, 2010</first_received>
    <start_date>March 2011</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>September 15, 2015</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>August 13, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to 44 Weeks</outcome_measure>
      <outcome_measure>Change in Ambulatory Capacity From Baseline to 44 Weeks</outcome_measure>
      <outcome_measure>Change in Schwab and England Scale From Baseline to 44 Weeks</outcome_measure>
      <outcome_measure>Change in Parkinson's Disease Questionnaire (PDQ-39) From Baseline to 44 Weeks</outcome_measure>
      <outcome_measure>Change in the Mattis Dementia Rating Scale (DRS-2)From Baseline to 44 Weeks</outcome_measure>
      <outcome_measure>Change in the 15-item Geriatric Depression Scale (GDS-15)From Baseline to 44 Weeks</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01280123</url>
  </study>
  <study rank="77">
    <title>Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[123I] 5-IA</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute for Neurodegenerative Disorders</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>November 7, 2006</first_received>
    <start_date>November 2006</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Radiotracer uptake in cortical regions in PD relative to Healthy Control subjects</outcome_measure>
      <outcome_measure>Nicotinic receptor as a reliable measure</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00397696</url>
  </study>
  <study rank="78">
    <title>Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Von Willebrand Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Biostate®</intervention>
      <intervention type="Biological">Biostate®</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>CSL Behring</lead_sponsor>
      <collaborator>Parexel</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 15, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>April 4, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Haemostatic efficacy at time of non-surgical bleeding (NSB) event</outcome_measure>
      <outcome_measure>Haemostatic efficacy overall</outcome_measure>
      <outcome_measure>Number of treatments with blood product transfusions required to resolve any bleeding event</outcome_measure>
      <outcome_measure>vWF/FVIII concentrate usage (number of infusions, IU/kg per dose, per event, per month and per year)</outcome_measure>
      <outcome_measure>Assessment of blood loss during any surgical procedure</outcome_measure>
      <outcome_measure>Number of spontaneous or traumatic NSB events</outcome_measure>
      <outcome_measure>Pharmacokinetic parameters for vWF and FVIII (PK arm only)</outcome_measure>
      <outcome_measure>Development of FVIII inhibitors</outcome_measure>
      <outcome_measure>Development of vWF inhibitors</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00941616</url>
  </study>
  <study rank="79">
    <title>A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SPM 962</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Otsuka Pharmaceutical Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>143</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 25, 2012</first_received>
    <start_date>January 2008</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>February 3, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>February 3, 2014</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters</outcome_measure>
      <outcome_measure>Skin Irritation Score of the Application Site</outcome_measure>
      <outcome_measure>Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01628965</url>
  </study>
  <study rank="80">
    <title>Safety Study of Erythropoietin (EPO) in Parkinson's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Erythropoietin human recombinant (EPOrh)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>International Center for Neurological Restoration, Cuba</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>45 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>November 8, 2009</first_received>
    <start_date>August 2008</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>November 9, 2009</last_updated>
    <last_verified>November 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>safety assessment measured by the absence of adverse events</outcome_measure>
      <outcome_measure>Post-treatment change in the motor score of the Unified Assessment Scale for Parkinson Disease´s (UPDRS) in the &quot;OFF&quot; condition as compared with the baseline.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01010802</url>
  </study>
  <study rank="81">
    <title>Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">certolizumab pegol</intervention>
      <intervention type="Drug">certolizumab pegol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UCB Pharma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>6 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 25, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>August 1, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of subjects reporting at least one Treatment-emergent Adverse Event (TEAE) during study treatment (up to 416 weeks)</outcome_measure>
      <outcome_measure>Number of subjects discontinuing treatment due to a Treatment-emergent Adverse Event (TEAE)</outcome_measure>
      <outcome_measure>Number of subjects who develop anti-nuclear antibodies during the study</outcome_measure>
      <outcome_measure>Number of subjects who develop double-stranded deoxyribonucleic acid (dsDNA) antibodies during the study</outcome_measure>
      <outcome_measure>Percentage of subjects in clinical remission</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01190410</url>
  </study>
  <study rank="82">
    <title>Searching for Persistence of Infection in Lyme Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lyme Disease</condition>
      <condition>Borrelia Burgdorferi</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Skin Biopsy</intervention>
      <intervention type="Device">Xenodiagnosis</intervention>
      <intervention type="Procedure">Blood Drawing</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>June 11, 2010</first_received>
    <start_date>May 2010</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>August 31, 2016</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Determine whether xenodiagnosis can detect the continued presence of B. burgdorferi in patients with Lyme disease after antibiotic therapy.</outcome_measure>
      <outcome_measure>Assess the safety of the planned xenodiagnostic procedure in humans.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01143558</url>
  </study>
  <study rank="83">
    <title>Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">nicotine</intervention>
      <intervention type="Other">placebo comparator</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Neuraltus Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>30 Years</min_age>
    <max_age>83 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>65</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 11, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>September 26, 2011</last_updated>
    <last_verified>September 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>frequency and severity of adverse events, active vs placebo</outcome_measure>
      <outcome_measure>measure of impulse control (rMIDI), active vs placebo</outcome_measure>
      <outcome_measure>measure of frequency and severity of dyskinesia (USDysRS), active vs placebo</outcome_measure>
      <outcome_measure>Parkinson's disease severity (UPDRS part II,III,IV), active vs placebo</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00957918</url>
  </study>
  <study rank="84">
    <title>Combined Deep Brain Stimulation for Parkinson's Disease</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">DBS Surgery</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>22 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>December 2, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>July 31, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Change in the amount of time needed to complete a standardized timed up and go (TUG) study at 6 months post-surgery on stimulation</outcome_measure>
      <outcome_measure>TUG study at 1, 3 and 12 months post-surgery.</outcome_measure>
      <outcome_measure>UPDRS III score and UPDRS III points 27-30 at 1, 3, 6 and 12 months</outcome_measure>
      <outcome_measure>PDQ 31 questionnaire at 6 months</outcome_measure>
      <outcome_measure>Swallowing function at 6 moths</outcome_measure>
      <outcome_measure>Static and dynamic posturography parameters at 1, 3, 6 and 12 months on stimulation.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01485276</url>
  </study>
  <study rank="85">
    <title>Autologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune Diseases</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Autoimmune Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Autologous hematopoietic stem cell transplantation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Charite University, Berlin, Germany</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 26, 2008</first_received>
    <start_date>January 1998</start_date>
    <last_updated>November 21, 2008</last_updated>
    <last_verified>November 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Disease-free survival</outcome_measure>
      <outcome_measure>Overall Survival</outcome_measure>
      <outcome_measure>Immune Reconstitution</outcome_measure>
      <outcome_measure>Organ-specific response parameters</outcome_measure>
      <outcome_measure>Serological Response (Autoantibodies)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00742300</url>
  </study>
  <study rank="86">
    <title>Mobile Health in Structural Heart Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Rheumatic Heart Disease</condition>
      <condition>Heart Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Device">mHealth</intervention>
      <intervention type="Other">Standard-Care</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sri Sathya Sai Institute of Higher Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>1 Year</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>253</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>August 18, 2016</first_received>
    <start_date>August 2014</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>August 23, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to definitive treatment with Valvuloplasty or Valve Replacement</outcome_measure>
      <outcome_measure>Cardiovascular Hospitalization and/or Death</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02881398</url>
  </study>
  <study rank="87">
    <title>Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">atomoxetine hydrochloride</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eli Lilly and Company</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>124</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double-Blind</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 12, 2005</first_received>
    <start_date>October 2003</start_date>
    <completion_date>January 2006</completion_date>
    <last_updated>November 5, 2007</last_updated>
    <last_verified>November 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To see if Alzheimer's patients receiving a stable dose of an Alzheimer's drug randomly assigned to atomoxetine for approximately 6 months will have cognitive performance improved as measured by the Alzheimer's Disease Assessment Scale - Cognitive</outcome_measure>
      <outcome_measure>To see if patients taking an Alzheimer's medication plus atomoxetine for approximately 6 months will be superior to an Alzheimer's medication alone as assessed by the Clinician's Interview-Based Impression of Change (CIBIC+) score.</outcome_measure>
      <outcome_measure>To see if patients taking an Alzheimer's medication plus atomoxetine will display less comorbid psychological symptoms, such as depression, as assessed by the Neuropsychiatric Inventory (NPI). Patients will receive the NPI once before randomization</outcome_measure>
      <outcome_measure>To see if current Alzheimer's medications plus atomoxetine compared to Alzheimer's medications plus placebo is better at preserving or slowing cognitive decline as measured by the Alzheimer's Disease Cooperative Study Inventory - Activities of</outcome_measure>
      <outcome_measure>To show that current Alzheimer's drugs can be taken with atomoxetine without significant side effects.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00191009</url>
  </study>
  <study rank="88">
    <title>Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifaximin-EIR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alfa Wassermann S.p.A.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>410</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 10, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>February 19, 2010</last_updated>
    <last_verified>February 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical remission (Crohn's Disease Activity Index &lt; 150 points)</outcome_measure>
      <outcome_measure>Clinical response (reduction of baseline CDAI score by 100 points or more)</outcome_measure>
      <outcome_measure>Clinical response (reduction of baseline CDAI by 70 points or more)</outcome_measure>
      <outcome_measure>Time to obtain clinical response and remission</outcome_measure>
      <outcome_measure>Maintenance of clinical remission</outcome_measure>
      <outcome_measure>Number of treatment failures</outcome_measure>
      <outcome_measure>Definition of therapeutic dose to be used in subsequent phase III trials.</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00528073</url>
  </study>
  <study rank="89">
    <title>Impact of Gum Infection on Heart Disease</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Disease</condition>
      <condition>Periodontal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Periodontal therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boston University</lead_sponsor>
      <collaborator>National Institute of Dental and Craniofacial Research (NIDCR)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>October 5, 2004</first_received>
    <start_date>September 2004</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>March 29, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Periodontal disease contributes to cardiovascular disease risk in human subjects and may lead to new approaches to therapy.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00093236</url>
  </study>
  <study rank="90">
    <title>Internet Chronic Disease Self-Management Program for Australia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Internet Chronic Disease Self-Management Program (ICDSMP)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <first_received>November 6, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>April 9, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Health Status</outcome_measure>
      <outcome_measure>Health behaviors</outcome_measure>
      <outcome_measure>Health care utilization</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00787956</url>
  </study>
  <study rank="91">
    <title>Standardized Fecal Microbiota Transplantation for Crohn&amp;Apos;s Diseases</title>
    <recruitment open="N">Unknown status</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Diseases</condition>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">FMT</intervention>
      <intervention type="Drug">5-ASA, Prednisone, Azathioprine or Remicade</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Second Hospital of Nanjing Medical University</lead_sponsor>
      <collaborator>Fourth Military Medical University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>14 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>February 13, 2013</first_received>
    <start_date>November 2012</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>November 21, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Clinical remission</outcome_measure>
      <outcome_measure>Hospitalization days</outcome_measure>
      <outcome_measure>Adverse events: fever and worsen abdominal pain.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01793831</url>
  </study>
  <study rank="92">
    <title>Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">UC-MSCs by peripheral intravenous infusion</intervention>
      <intervention type="Drug">received hormone maintenance therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fuzhou General Hospital</lead_sponsor>
      <collaborator>Shaanxi Provincial People's Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 13, 2015</first_received>
    <start_date>June 2012</start_date>
    <last_updated>November 16, 2016</last_updated>
    <last_verified>November 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Crohn's disease activity index</outcome_measure>
      <outcome_measure>Harvey-Bradshaw index</outcome_measure>
      <outcome_measure>Corticosteroid dosage</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT02445547</url>
  </study>
  <study rank="93">
    <title>A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease &amp; Chronic Constipation</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RM-131</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Motus Therapeutics, Inc.</lead_sponsor>
      <collaborator>Michael J. Fox Foundation for Parkinson's Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>September 25, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>September 21, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Investigate the effects of treatment with RM-131 for 14 days on the frequency of spontaneous bowel movements (SBMs) when administered to patients with Parkinson's Disease (PD) and Chronic Constipation (CC)</outcome_measure>
      <outcome_measure>Evaluate the safety and tolerability of multiple doses of RM-131 when administered to patients with PD and CC</outcome_measure>
      <outcome_measure>Effect of RM-131 on stool frequency as measured by complete spontaneous bowel movements, stool consistency, straining, completeness of evacuation, abdominal pain, and global patient reported outcomes of severity of constipation and overall relief.</outcome_measure>
      <outcome_measure>Assess symptoms of Parkinson's disease using the Unified Parkinson Disease Rating Scale (UPDRS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01955616</url>
  </study>
  <study rank="94">
    <title>Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">coenzyme q10</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National University Hospital, Singapore</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Months</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>June 30, 2013</first_received>
    <start_date>June 2012</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>July 8, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Biomarkers of oxidative damage</outcome_measure>
      <outcome_measure>Total Unified Parkinson's Disease Rating Scale (UPDRS)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01892176</url>
  </study>
  <study rank="95">
    <title>A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dimebon</intervention>
      <intervention type="Drug">Dimebon</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medivation, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>598</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>May 7, 2008</first_received>
    <start_date>May 2008</start_date>
    <last_updated>September 24, 2016</last_updated>
    <last_verified>September 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the effect of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog).</outcome_measure>
      <outcome_measure>To determine the effect of Dimebon as compared to placebo on the primary measure of global function, the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus).</outcome_measure>
      <outcome_measure>To determine the effect of Dimebon as compared to placebo on a measure of self care and daily function, the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL).</outcome_measure>
      <outcome_measure>To determine the effect of Dimebon as compared to placebo on a measure of behavior, the Neuropsychiatric Inventory (NPI).</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00675623</url>
  </study>
  <study rank="96">
    <title>Telemonitoring to Improve Outcomes of Patients With Chronic Kidney Disease (CKD)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Video Telemonitoring Device with Clinical Care Modules</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Minneapolis Veterans Affairs Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>601</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <first_received>September 28, 2011</first_received>
    <start_date>March 2012</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>August 1, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>composite clinical outcome (reduce risk of death, hospitalization, emergency room visits, admission to skilled nursing facility)</outcome_measure>
      <outcome_measure>reduction of cost</outcome_measure>
      <outcome_measure>incidence of end stage kidney disease</outcome_measure>
      <outcome_measure>hospital re-admission</outcome_measure>
      <outcome_measure>Intervention group achieving National Kidney guideline values for blood pressure, glycemia, lipids, and hemoglobin</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT01446029</url>
  </study>
  <study rank="97">
    <title>Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PF-04360365 0.1 mg/kg</intervention>
      <intervention type="Biological">PF-04360365 0.5 mg/kg</intervention>
      <intervention type="Biological">PF-04360365 1 mg/kg</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Biological">PF-04360365 3 mg/kg</intervention>
      <intervention type="Biological">PF-04360365 8.5 mg/kg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>198</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 23, 2008</first_received>
    <start_date>December 2008</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>April 8, 2016</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety/tolerability of PF-04360365 in subjects with mild to moderate Alzheimer's disease dosed for 18 months. (adverse events, physical/neurologic exams, vital signs, 12-lead ECG, clinical labs, brain MRI, cognitive assessments)</outcome_measure>
      <outcome_measure>Pharmacokinetics of PF-04360365 following administration of multiple doses in subjects with mild to moderate Alzheimer's disease. (plasma and cerebrospinal fluid (as available) PF-04360365 concentrations)</outcome_measure>
      <outcome_measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog); Disability Assessment for Dementia (DAD); plasma/CSF Abeta; CSF tau and phosphotau; CSF protein, RBCs, WBCs and glucose; Immunogenicity (anti-drug antibodies)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00722046</url>
  </study>
  <study rank="98">
    <title>Tolerance and Efficacy of Rituximab in Sjogren's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sjogren's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rituximab (mabthera) Injection</intervention>
      <intervention type="Drug">Placebo: NaCl 0.9% or Glucose 5%</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Brest</lead_sponsor>
      <collaborator>Ministry of Health, France</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>122</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>August 22, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>March 4, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>30% improvement between in the values on 2 of the 4 VAS measuring global scores of the disease (activity of the disease), joint pain, fatigue, and dryness.</outcome_measure>
      <outcome_measure>Variations from baseline to week 24 of clinical, biological and histological data</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00740948</url>
  </study>
  <study rank="99">
    <title>Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Pre-hypertension</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">carvedilol phosphate</intervention>
      <intervention type="Drug">lisinopril</intervention>
      <intervention type="Drug">carvedilol phosphate and lisinopril</intervention>
      <intervention type="Drug">placebo and placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Minnesota - Clinical and Translational Science Institute</lead_sponsor>
      <collaborator>GlaxoSmithKline</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>101</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>November 5, 2007</first_received>
    <start_date>November 2007</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>December 9, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 16, 2013</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Overall Rasmussen Disease Score (RDS) Change From Baseline to 9 Months Will be the Primary End-point.</outcome_measure>
      <outcome_measure>Change in Disease Score (DS) Among the Treatment Groups</outcome_measure>
      <outcome_measure>Quantitative Change in Each of the RDS Components From Baseline to 9 Months Will Serve as a Secondary End-point. The 3-month Data Will Provide Early Evidence for Drug Efficacy and Will be Analyzed Similarly as a Secondary End-point.</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00553969</url>
  </study>
  <study rank="100">
    <title>A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PF-04360365 10 mg/kg</intervention>
      <intervention type="Biological">PF-04360365 7.5 mg/kg</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <first_received>July 22, 2009</first_received>
    <start_date>August 2009</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>April 8, 2016</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety/tolerability/PK of multiple doses of PF-04360365 in subjects with mild to moderate Alzheimer's disease dosed for 1 year (adverse events, physical/neurological exams, vital signs, 12-lead ECG, clinical labs, brain MRI, cognitive assessments)</outcome_measure>
      <outcome_measure>Brain amyloid burden</outcome_measure>
      <outcome_measure>CSF abeta</outcome_measure>
      <outcome_measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog); Disability Assessment for Dementia (DAD); plasma abeta, CSF tau and phosphotau; CSF protein, RBCs, WBCs and glucose; immunogenicity (anti-drug antibodies)</outcome_measure>
    </outcome_measures>
    <url>https://ClinicalTrials.gov/show/NCT00945672</url>
  </study>
</search_results>
